SCHEMBL2700622

SCHEMBL2700622

Cc1cccc(C(=O)Nc2ccc(Cl)cc2)c1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.67
NPC1 O15118 2/20 0.67
KDM4E B2RXH2 1/20 0.67
ALDH1A1 P00352 1/20 0.67
HTT P42858 1/20 0.67
RAB9A P51151 1/20 0.67
PLAU P00749 2/20 0.66
F10 P00742 2/20 0.66
F2 P00734 1/20 0.66
PLG P00747 1/20 0.66
PLAT P00750 1/20 0.66
KLK1 P06870 1/20 0.66
KLK5 Q9Y337 1/20 0.66
P2RX1 P51575 2/20 0.58
BCL2L1 Q07817 1/20 0.58
DHODH Q02127 1/20 0.56
KLKB1 P03952 1/20 0.55
HPGD P15428 1/20 0.54
PNLIP P16233 1/20 0.54
KDR P35968 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7764478 0.85 HPGD (0.74) SMN1; SMN2KDM4EALDH1A1HTTPLAU
SCHEMBL2119568 0.85 HPGD (0.74) SMN1; SMN2NPC1ALDH1A1HTTRAB9A
SCHEMBL2703391 0.85 FADS1 (0.67) SMN1; SMN2NPC1KDM4EALDH1A1HTT
SCHEMBL2702708 0.84 PLAU (0.66) SMN1; SMN2NPC1KDM4EALDH1A1RAB9A
SCHEMBL6592137 0.83 HPGD (0.53) SMN1; SMN2NPC1ALDH1A1HTTRAB9A
SCHEMBL21336584 0.81 PNLIP (0.61) SMN1; SMN2NPC1KDM4EHTTRAB9A
SCHEMBL14340061 0.81 KLKB1 (0.58) NPC1PLAUF10F2PLAT
SCHEMBL7077100 0.81 SMN1; SMN2 (0.60) SMN1; SMN2NPC1ALDH1A1RAB9APLAU
SCHEMBL10192462 0.80 PLAU (0.67) SMN1; SMN2NPC1KDM4EALDH1A1HTT
SCHEMBL27778782 0.78 TYK2 (0.55) SMN1; SMN2NPC1HTTRAB9AP2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012058378-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES ROMARK LABORATORIES L.C. (US) 2012-05-03 WO disclosed
US-20120108592-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES ROMARK LABORATORIES, L.C. 2012-05-03 US disclosed
US-20120108592-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES ROMARK LABORATORIES, L.C. 2012-05-03 US disclosed
US-20120108592-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES ROMARK LABORATORIES, L.C. 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108592-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES PYGL, GYS2, GLS2 SMN1; SMN2 3414/4885NPC1 2616/4885KDM4E 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.